Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015)

Yamada, Daisaku; Kobayashi, Shogo; Takahashi, Hidenori; Iwagami, Yoshifumi; Akita, Hirofumi; Asukai, Kei; Shimizu, Junzo; Yamada, Terumasa; Tanemura, Masahiro; Yokoyama, Shigekazu; Tsujie, Masanori; Asaoka, Tadafumi; Takeda, Yutaka; Morimoto, Osakuni; Tomokuni, Akira; Doki, Yuichiro; Eguchi, Hidetoshi

doi:https://doi.org/10.1245/s10434-024-15199-8

Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015)

Yamada, Daisaku; Kobayashi, Shogo; Takahashi, Hidenori et al.

Annals of Surgical Oncology, 2024, 31, 4621-4633

アクセス数:95件（2025-04-28 19:06 集計）

固定URL: https://hdl.handle.net/11094/95727

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
AnnSurgOncol_15199_8	pdf	なし	684 KB	90	2024.05.28

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015)
著者	NRID 1000060571396 1000060571396 ORCID 0000-0002-6702-3800 0000-0002-6702-3800 researchmap permalink dyamada79222 dyamada79222 Scopus Author ID 37008067700 37008067700 著者名 Yamada, Daisaku
	NRID 1000030452436 1000030452436 researchmap permalink 30452436 30452436 Scopus Author ID 7405376089 7405376089 ORCID 0000-0002-8828-1067 0000-0002-8828-1067 著者名 Kobayashi, Shogo
	NRID 1000090601120 1000090601120 ORCID 0000-0003-4801-3540 0000-0003-4801-3540 researchmap permalink hdnr_tkhs hdnr_tkhs Scopus Author ID 7405468781 7405468781 著者名 Takahashi, Hidenori
	NRID 1000060597441 1000060597441 researchmap permalink yiwagami yiwagami Scopus Author ID 35074034100 35074034100 著者名 Iwagami, Yoshifumi
	NRID 1000070528463 1000070528463 researchmap permalink hirofumi_akita hirofumi_akita 著者名 Akita, Hirofumi
	著者名 Asukai, Kei
	著者名 Shimizu, Junzo
	著者名 Yamada, Terumasa
	NRID 1000030379250 1000030379250 researchmap permalink read0118541 read0118541 著者名 Tanemura, Masahiro
	著者名 Yokoyama, Shigekazu
	著者名 Tsujie, Masanori
	NRID 1000060528470 1000060528470 著者名 Asaoka, Tadafumi
	著者名 Takeda, Yutaka
	著者名 Morimoto, Osakuni
	著者名 Tomokuni, Akira
	NRID 1000020291445 1000020291445 researchmap permalink ydoki3251 ydoki3251 Scopus Author ID 7006390687 7006390687 著者名 Doki, Yuichiro
	NRID 1000090542118 1000090542118 researchmap permalink abcdabcdabcd abcdabcdabcd Scopus Author ID 7101627772 7101627772 著者名 Eguchi, Hidetoshi
キーワード等	GEM+nPTX
	GEM+S-1
	NAC
	R-PDAC
	R/BR-PDAC
内容	The version of record of this article, first published in Annals of Surgical Oncology, is available online at Publisher’s website: https://doi.org/10.1245/s10434-024-15199-8.
抄録	Background: The optimal neoadjuvant chemotherapy (NAC) regimen for patients with localized pancreatic ductal adenocarcinoma (PDAC) remains uncertain. This trial aimed to evaluate the efficacy and safety of two neoadjuvant chemotherapy (NAC) regimens, gemcitabine plus nab-paclitaxel (GA) and gemcitabine plus S-1 (GS), in patients with resectable/borderline-resectable (R/BR) PDAC. Patients and Methods: Treatment-naïve patients with R/BR-PDAC were enrolled and randomly allocated. They received two cycles (2 months) of each standard protocol, followed by radical surgery for those without tumor progression in general hospitals belonging to our intergroup. The primary endpoint was to determine the superior regimen on the basis of achieving a 10% increase in the rate of patients with progression-free survival (PFS) at 2 years from allocation. Results: A total of 100 patients were enrolled, with 94 patients randomly assigned to the GS arm (N = 46) or GA arm (N = 48). The 2-year PFS rates did not show the stipulated difference [GA, 31% (24–38%)/GS, 26% (18–33%)], but the Kaplan–Myer analysis showed significance (median PFS, GA/GS 14 months/9 months, P = 0.048; HR 0.71). Secondary endpoint comparisons yielded the following results (GA/GS arm, P-value): rates of severe adverse events during NAC, 73%/78%, P = 0.55; completion rates of the stipulated NAC, 92%/83%, P = 0.71; resection rates, 85%/72%, P = 0.10; average tumor marker (CA19-9) reduction rates, −50%/−21%, P = 0.01; average numbers of lymph node metastasis, 1.7/3.2, P = 0.04; and median overall survival times, 42/22 months, P = 0.26. Conclusions: This study found that GA and GS are viable neoadjuvant treatment regimens in R/BR-PDAC. Although the GA group exhibited a favorable PFS outcome, the primary endpoint was not achieved.
出版者	Springer
収録物名	Annals of Surgical Oncology
巻(号)	31
ページ	4621-4633
刊行年月	2024-03-28
言語	英語
ハンドルURL	https://hdl.handle.net/11094/95727
PISSN	10689265
eISSN	15344681
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1245/s10434-024-15199-8
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Annals of Surgical Oncology. 2024, 31, p. 4621-4633
DC.title	Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015)
DC.creator	Yamada, Daisaku
	Kobayashi, Shogo
	Takahashi, Hidenori
	Iwagami, Yoshifumi
	Akita, Hirofumi
	Asukai, Kei
	Shimizu, Junzo
	Yamada, Terumasa
	Tanemura, Masahiro
	Yokoyama, Shigekazu
	Tsujie, Masanori
	Asaoka, Tadafumi
	Takeda, Yutaka
	Morimoto, Osakuni
	Tomokuni, Akira
	Doki, Yuichiro
	Eguchi, Hidetoshi
DC.publisher	Springer
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-03-28
DC.identifier	https://doi.org/10.1245/s10434-024-15199-8
DC.subject	GEM+nPTX
	GEM+S-1
	NAC
	R-PDAC
	R/BR-PDAC
DC.description	The version of record of this article, first published in Annals of Surgical Oncology, is available online at Publisher’s website: https://doi.org/10.1245/s10434-024-15199-8.
DCTERMS.abstract	Background: The optimal neoadjuvant chemotherapy (NAC) regimen for patients with localized pancreatic ductal adenocarcinoma (PDAC) remains uncertain. This trial aimed to evaluate the efficacy and safety of two neoadjuvant chemotherapy (NAC) regimens, gemcitabine plus nab-paclitaxel (GA) and gemcitabine plus S-1 (GS), in patients with resectable/borderline-resectable (R/BR) PDAC. Patients and Methods: Treatment-naïve patients with R/BR-PDAC were enrolled and randomly allocated. They received two cycles (2 months) of each standard protocol, followed by radical surgery for those without tumor progression in general hospitals belonging to our intergroup. The primary endpoint was to determine the superior regimen on the basis of achieving a 10% increase in the rate of patients with progression-free survival (PFS) at 2 years from allocation. Results: A total of 100 patients were enrolled, with 94 patients randomly assigned to the GS arm (N = 46) or GA arm (N = 48). The 2-year PFS rates did not show the stipulated difference [GA, 31% (24–38%)/GS, 26% (18–33%)], but the Kaplan–Myer analysis showed significance (median PFS, GA/GS 14 months/9 months, P = 0.048; HR 0.71). Secondary endpoint comparisons yielded the following results (GA/GS arm, P-value): rates of severe adverse events during NAC, 73%/78%, P = 0.55; completion rates of the stipulated NAC, 92%/83%, P = 0.71; resection rates, 85%/72%, P = 0.10; average tumor marker (CA19-9) reduction rates, −50%/−21%, P = 0.01; average numbers of lymph node metastasis, 1.7/3.2, P = 0.04; and median overall survival times, 42/22 months, P = 0.26. Conclusions: This study found that GA and GS are viable neoadjuvant treatment regimens in R/BR-PDAC. Although the GA group exhibited a favorable PFS outcome, the primary endpoint was not achieved.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	95727
citation_title	Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015)
citation_author	Yamada, Daisaku
	Kobayashi, Shogo
	Takahashi, Hidenori
	Iwagami, Yoshifumi
	Akita, Hirofumi
	Asukai, Kei
	Shimizu, Junzo
	Yamada, Terumasa
	Tanemura, Masahiro
	Yokoyama, Shigekazu
	Tsujie, Masanori
	Asaoka, Tadafumi
	Takeda, Yutaka
	Morimoto, Osakuni
	Tomokuni, Akira
	Doki, Yuichiro
	Eguchi, Hidetoshi
citation_publisher	Springer
citation_language	英語
citation_date	2024-03-28
citation_journal_title	Annals of Surgical Oncology
citation_volume	31
citation_firstpage	4621
citation_lastpage	4633
citation_doi	https://doi.org/10.1245/s10434-024-15199-8
citation_public_url	https://hdl.handle.net/11094/95727

Results of a Randomized Clinical Study of Gemcitabine Plus Nab-Paclitaxel Versus Gemcitabine Plus S-1 as Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma (RCT, CSGO-HBP-015)

閲覧可能ファイル

論文情報

論文詳細を表示